These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 29720964)

  • 1. Preoperative Molecular Markers in Thyroid Nodules.
    Sahli ZT; Smith PW; Umbricht CB; Zeiger MA
    Front Endocrinol (Lausanne); 2018; 9():179. PubMed ID: 29720964
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular testing for indeterminate thyroid nodules: Performance of the Afirma gene expression classifier and ThyroSeq panel.
    Jug RC; Datto MB; Jiang XS
    Cancer Cytopathol; 2018 Jul; 126(7):471-480. PubMed ID: 29637728
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thyroseq v3, Afirma GSC, and microRNA Panels Versus Previous Molecular Tests in the Preoperative Diagnosis of Indeterminate Thyroid Nodules: A Systematic Review and Meta-Analysis.
    Silaghi CA; Lozovanu V; Georgescu CE; Georgescu RD; Susman S; Năsui BA; Dobrean A; Silaghi H
    Front Endocrinol (Lausanne); 2021; 12():649522. PubMed ID: 34054725
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Single Institution Experience with Afirma and Thyroseq Testing in Indeterminate Thyroid Nodules.
    Gortakowski M; Feghali K; Osakwe I
    Thyroid; 2021 Sep; 31(9):1376-1382. PubMed ID: 33764195
    [No Abstract]   [Full Text] [Related]  

  • 5. Evaluation of 167 Gene Expression Classifier (GEC) and ThyroSeq v2 Diagnostic Accuracy in the Preoperative Assessment of Indeterminate Thyroid Nodules: Bivariate/HROC Meta-analysis.
    Borowczyk M; Szczepanek-Parulska E; Olejarz M; Więckowska B; Verburg FA; Dębicki S; Budny B; Janicka-Jedyńska M; Ziemnicka K; Ruchała M
    Endocr Pathol; 2019 Mar; 30(1):8-15. PubMed ID: 30591992
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gene Expression Classifier vs Targeted Next-Generation Sequencing in the Management of Indeterminate Thyroid Nodules.
    Livhits MJ; Kuo EJ; Leung AM; Rao J; Levin M; Douek ML; Beckett KR; Zanocco KA; Cheung DS; Gofnung YA; Smooke-Praw S; Yeh MW
    J Clin Endocrinol Metab; 2018 Jun; 103(6):2261-2268. PubMed ID: 29590358
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnostic accuracy of Afirma gene expression classifier, Afirma gene sequencing classifier, ThyroSeq v2 and ThyroSeq v3 for indeterminate (Bethesda III and IV) thyroid nodules: a meta-analysis.
    Vardarli I; Tan S; Görges R; Krämer BK; Herrmann K; Brochhausen C
    Endocr Connect; 2024 Jul; 13(7):. PubMed ID: 38771544
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Afirma Gene Sequencing Classifier Compared with Gene Expression Classifier in Indeterminate Thyroid Nodules.
    Endo M; Nabhan F; Porter K; Roll K; Shirley LA; Azaryan I; Tonkovich D; Perlick J; Ryan LE; Khawaja R; Meng S; Phay JE; Ringel MD; Sipos JA
    Thyroid; 2019 Aug; 29(8):1115-1124. PubMed ID: 31154940
    [No Abstract]   [Full Text] [Related]  

  • 9. Evaluation of ThyroSeq v2 performance in thyroid nodules with indeterminate cytology.
    Valderrabano P; Khazai L; Leon ME; Thompson ZJ; Ma Z; Chung CH; Hallanger-Johnson JE; Otto KJ; Rogers KD; Centeno BA; McIver B
    Endocr Relat Cancer; 2017 Mar; 24(3):127-136. PubMed ID: 28104680
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-risk and intermediate-high-risk results from the ThyroSeq v2 and v3 thyroid genomic classifier are associated with neoplasia: Independent performance assessment at an academic institution.
    Jug R; Foo WC; Jones C; Ahmadi S; Jiang XS
    Cancer Cytopathol; 2020 Aug; 128(8):563-569. PubMed ID: 32339438
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Performance of Afirma genomic sequencing classifier vs gene expression classifier in Bethesda category III thyroid nodules: An institutional experience.
    Zhang L; Smola B; Lew M; Pang J; Cantley R; Pantanowitz L; Heider A; Jing X
    Diagn Cytopathol; 2021 Aug; 49(8):921-927. PubMed ID: 34021740
    [TBL] [Abstract][Full Text] [Related]  

  • 12. American Thyroid Association Sonographic Risk and Afirma Gene Expression Classifier Alone and in Combination for the Diagnosis of Thyroid Nodules with Bethesda Category III Cytology.
    Arosemena M; Thekkumkattil A; Valderrama ML; Kuker R; Castillo RP; Sidani C; Gonzalez ML; Casula S; Kargi AY
    Thyroid; 2020 Nov; 30(11):1613-1619. PubMed ID: 32364010
    [No Abstract]   [Full Text] [Related]  

  • 13. ThyroSeq
    Rivas AM; Nassar A; Zhang J; Casler JD; Chindris AM; Smallridge R; Bernet V
    Endocr Pract; 2018 Sep; 24(9):780-788. PubMed ID: 30084677
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of Afirma Gene Expression Classifier with Gene Sequencing Classifier in indeterminate thyroid nodules: A single-institutional experience.
    Geng Y; Aguilar-Jakthong JS; Moatamed NA
    Cytopathology; 2021 Mar; 32(2):187-191. PubMed ID: 33010060
    [TBL] [Abstract][Full Text] [Related]  

  • 15. UTILITY OF AFIRMA GENE EXPRESSION CLASSIFIER FOR EVALUATION OF INDETERMINATE THYROID NODULES AND CORRELATION WITH ULTRASOUND RISK ASSESSMENT: SINGLE INSTITUTIONAL EXPERIENCE.
    Sultan R; Levy S; Sulanc E; Honasoge M; Rao SD
    Endocr Pract; 2020 May; 26(5):543-551. PubMed ID: 31968199
    [No Abstract]   [Full Text] [Related]  

  • 16. Hurthle cell predominance impacts results of Afirma gene expression classifier and ThyroSeq molecular panel performance in indeterminate thyroid nodules.
    Parajuli S; Jug R; Ahmadi S; Jiang XS
    Diagn Cytopathol; 2019 Nov; 47(11):1177-1183. PubMed ID: 31348619
    [TBL] [Abstract][Full Text] [Related]  

  • 17. COMMUNITY ENDOCRINE SURGICAL EXPERIENCE WITH FALSE-NEGATIVE AFIRMA GEC
    Harrell RM; Eyerly-Webb SA; Pinnar NE; Golding AC; Edwards CM; Bimston DN
    Endocr Pract; 2018 Jul; 24(7):622-627. PubMed ID: 29688761
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of noninvasive follicular thyroid neoplasm with papillary-like nuclear features on the performance of the Afirma gene expression classifier.
    Hang JF; Westra WH; Cooper DS; Ali SZ
    Cancer Cytopathol; 2017 Sep; 125(9):683-691. PubMed ID: 28544601
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular Testing Has Limited Utility in the Surgical Evaluation of Bethesda III Thyroid Nodules.
    Scola WH; Linhares SM; Handelsman RS; Picado O; Khan ZF; Farrá JC; Lew JI
    J Surg Res; 2021 Dec; 268():209-213. PubMed ID: 34358733
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An independent study of a gene expression classifier (Afirma) in the evaluation of cytologically indeterminate thyroid nodules.
    McIver B; Castro MR; Morris JC; Bernet V; Smallridge R; Henry M; Kosok L; Reddi H
    J Clin Endocrinol Metab; 2014 Nov; 99(11):4069-77. PubMed ID: 24780044
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.